Nucl Med Mol Imaging.  2024 Oct;58(5):257-278. 10.1007/s13139-024-00860-7.

Recent Progress in Synthesis of^99m Tc‑labeled Complexes with Nitroimidazoles as SPECT Probes for Targeting Tumor Hypoxia

• Nguyen A
• Kim H

• KMID: 2560633
• DOI: http://doi.org/10.1007/s13139-024-00860-7

Abstract

The majority of solid tumors have hypoxia, or low oxygen levels, which is one of the hallmarks of cancer. Hypoxia was found to relate to cancer metastases and resistance to therapies, therefore, detection of hypoxia plays an important role in the process of cancer prognosis and treatment. Single-photon emission computed tomography (SPECT) is a non-invasive imaging technique using gamma-emitting radiopharmaceuticals to visualize biological activities within the body. SPECT is also applied for the detection of tumor hypoxia with the development of hypoxia-targeting radiopharmaceuticals. Radiopharmaceuticals containing nitroimidazole moieties have received increasing attention due to their bio-reducible characteristics which make the radiopharmaceuticals accumulate in the hypoxia regions. This review summarizes the recent development of^99m Tc-labeled radiopharmaceuticals bearing nitroimidazoles for SPECT imaging of tumor hypoxia including the synthetic methods and results of animal studies.

Keyword

Technesium-99 m; Radiopharmaceuticals; Hypoxia; Tumor; SPECT